1. Home
  2. PODD vs OKTA Comparison

PODD vs OKTA Comparison

Compare PODD & OKTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PODD
  • OKTA
  • Stock Information
  • Founded
  • PODD 2000
  • OKTA 2009
  • Country
  • PODD United States
  • OKTA United States
  • Employees
  • PODD N/A
  • OKTA N/A
  • Industry
  • PODD Medical/Dental Instruments
  • OKTA Computer Software: Prepackaged Software
  • Sector
  • PODD Health Care
  • OKTA Technology
  • Exchange
  • PODD Nasdaq
  • OKTA Nasdaq
  • Market Cap
  • PODD 21.5B
  • OKTA 17.7B
  • IPO Year
  • PODD 2007
  • OKTA 2017
  • Fundamental
  • Price
  • PODD $290.28
  • OKTA $92.94
  • Analyst Decision
  • PODD Strong Buy
  • OKTA Buy
  • Analyst Count
  • PODD 19
  • OKTA 39
  • Target Price
  • PODD $320.11
  • OKTA $122.34
  • AVG Volume (30 Days)
  • PODD 767.5K
  • OKTA 3.0M
  • Earning Date
  • PODD 08-07-2025
  • OKTA 08-27-2025
  • Dividend Yield
  • PODD N/A
  • OKTA N/A
  • EPS Growth
  • PODD 67.46
  • OKTA N/A
  • EPS
  • PODD 5.55
  • OKTA 0.63
  • Revenue
  • PODD $2,198,900,000.00
  • OKTA $2,681,000,000.00
  • Revenue This Year
  • PODD $24.49
  • OKTA $11.88
  • Revenue Next Year
  • PODD $17.45
  • OKTA $9.69
  • P/E Ratio
  • PODD $52.13
  • OKTA $144.76
  • Revenue Growth
  • PODD 23.48
  • OKTA 13.51
  • 52 Week Low
  • PODD $173.00
  • OKTA $70.56
  • 52 Week High
  • PODD $329.33
  • OKTA $127.57
  • Technical
  • Relative Strength Index (RSI)
  • PODD 36.89
  • OKTA 31.04
  • Support Level
  • PODD $293.38
  • OKTA $96.58
  • Resistance Level
  • PODD $300.00
  • OKTA $99.88
  • Average True Range (ATR)
  • PODD 7.24
  • OKTA 2.46
  • MACD
  • PODD -1.88
  • OKTA 0.03
  • Stochastic Oscillator
  • PODD 6.98
  • OKTA 3.70

About PODD Insulet Corporation

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.

About OKTA Okta Inc.

Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.

Share on Social Networks: